Key result
The TNFalpha-308 G/A genotype was significantly more frequent in rheumatoid arthritis patients compared to healthy subjects (OR 2.9; 95% CI 1.05-8.08; P=0.03).
Why the study?
Are TNFalpha-308 and -238 polymorphisms associated with rheumatoid arthritis susceptibility and TNFalpha expression?
Case-Control (n=150)
Are TNFalpha-308 and -238 polymorphisms associated with rheumatoid arthritis susceptibility and TNFalpha expression?
Odds Ratio: 2.9 (95% CI 1.05–8.08)
p-value: p=0.03
The TNFalpha-308 polymorphism is a susceptibility marker for rheumatoid arthritis and is associated with high mRNA and soluble TNFalpha expression.
TNFα-308 G/A association with RA susceptibility is hypothesis-generating; does not support clinical genotyping or risk modification.
BACKGROUND: Rheumatoid arthritis (RA) is characterized by a progressive joint damage mediated mainly by tumor necrosis factor alpha (TNFalpha). We investigated the relationship of TNFalpha-308 and -238 polymorphisms with messenger RNA (mRNA) expression and soluble TNFalpha (sTNFalpha) in 50 RA and 100 healthy subjects (HS). METHODS: Clinical and laboratory assessments were performed. Spanish Health Assessment Questionnaire Disability Index, Spanish version of Arthritis Impact Measurement Scales and Disease Activity Score using 28 joint count indices were applied to RA patients. The TNFalpha-308 and -238 polymorphisms were performed by polymerase chain reaction and restriction fragment length polymorphism techniques. The mRNA expression of TNFalpha was quantified by real-time polymerase chain reaction. The sTNFalpha levels were measured by enzyme-linked immunosorbent assay. RESULTS: The TNFalpha-308 polymorphism showed an increased frequency of guanine (G)/adenine (A) genotype in RA versus HS (P = 0.03; 95% confidence interval, 1.05-8.08; odds ratio, 2.9) and also the A allele was more frequent in RA patients versus HS (P = 0.04; 95% confidence interval, 1.01-7.29; odds ratio, 2.7). The G/G genotype and also the G allele were more frequent in HS. No significant difference was observed in TNFalpha-238 polymorphism. Rheumatoid arthritis patients showed high TNFalpha mRNA expression (1.33-fold). The G/G genotype was associated with high mRNA and sTNFalpha levels in both TNFalpha polymorphisms. The correlation of sTNFalpha levels with C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, Spanish Health Assessment Questionnaire Disability Index, and Spanish version of Arthritis Impact Measurement Scales, was observed. CONCLUSION: The TNFalpha-308 polymorphism is a susceptibility marker to RA. The G/G genotype is associated with a high mRNA and soluble TNFalpha expression.
No takes yet. Share an insight, caveat, or question.
Oregon‐Romero et al. (2008) conducted a case-control in Rheumatoid arthritis (n=150). TNFalpha-308 and -238 polymorphisms vs. Healthy subjects was evaluated on Frequency of TNFalpha-308 G/A genotype (OR 2.9, 95% CI 1.05-8.08, p=0.03). The TNFalpha-308 G/A genotype was significantly more frequent in rheumatoid arthritis patients compared to healthy subjects (OR 2.9; 95% CI 1.05-8.08; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: